FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Pare Anthony
2. Date of Event Requiring Statement (MM/DD/YYYY)
1/13/2020 

3. Issuer Name and Ticker or Trading Symbol

T2 Biosystems, Inc. [TTOO]
(Last)        (First)        (Middle)

101 HARTWELL AVENUE
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
Chief Commercial Officer /
(Street)

LEXINGTON, MA 02421      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 4577 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option  (1)4/8/2029 Common Stock 100000 $3.10 D  
Stock Option  (2)9/10/2029 Common Stock 100000 $1.43 D  
Stock Option  (3)1/8/2030 Common Stock 150000 $1.15 D  

Explanation of Responses:
(1) This Stock Option was granted on April 8, 2019 and vesting commenced on the grant date. Options to purchase 25% of the total underlying shares vest on the first anniversary of the vesting commencement date and options to purchase the remaining shares vest in 36 equal monthly installments thereafter.
(2) This Stock Option was granted on September 10, 2019 and vests in 48 equal monthly installments beginning on the grant date.
(3) This Stock Option was granted on January 8, 2020 and vests in 48 equal monthly installments beginning on the grant date.

Remarks:
Exhibit List: Exhibit 24 - Power of Attorney

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Pare Anthony
101 HARTWELL AVENUE
LEXINGTON, MA 02421


Chief Commercial Officer

Signatures
/s/ Michael Gibbs, Attorney-in-fact1/29/2020
**Signature of Reporting PersonDate

T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Apr 2020 to May 2020 Click Here for more T2 Biosystems Charts.
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From May 2019 to May 2020 Click Here for more T2 Biosystems Charts.